Trials
5 active
7 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive ALKS 2680 tablets, orally, daily, for 12 weeks”In the company’s words, NCT07455383 on ClinicalTrials.gov
- Tested for
- Narcolepsy Type 1 (3 trials), Narcolepsy Type 2 (2 trials), Idiopathic Hypersomnia (2 trials)
- Main trialPhase 3
- “The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.”In the company’s words, NCT07455383 on ClinicalTrials.gov
- Other names
- Alixorexton
Other drugs for Narcolepsy Type 1
- OveporextonTakeda · Phase 3
- CleminorextonCentessa Pharmaceuticals (UK) Limited · Phase 2/3
- PitolisantHarmony Biosciences · Phase 3
- SamelisantSuven Life Sciences Limited · Phase 3
- XywavJazz Pharmaceuticals · Phase 3
- E2086Eisai · Phase 2
Coming up5
- NovPhase 2 trial completes · ClinicalTrials.gov
- May 2027Phase 3 trial completes · ClinicalTrials.gov
- May 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2027 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | |
| Phase 3Recruiting | May 2027 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | |
| Phase 3Recruiting | Jun 2027 | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | |
| Phase 2/3Recruiting | Jun 2030 | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | |
| Phase 2Active, not recruiting | Nov 2026 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | |
| Phase 2Completed | 19 Jun 2025 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) | |
| Phase 2Completed | 11 Nov 2025 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026